Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Apr 18 2018 Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
- Apr 16 2018 Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
- Apr 4 2018 Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
- Apr 2 2018 Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference